Premium
Using a lipidomic approach to reveal omega‐3 response phenotypes (635.1)
Author(s) -
Zivkovic Angela
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.635.1
Subject(s) - oxylipin , eicosapentaenoic acid , docosahexaenoic acid , arachidonic acid , fatty acid , biology , polyunsaturated fatty acid , medicine , endocrinology , chemistry , biochemistry , physiology , gene , enzyme
The potential benefits of ω3 fatty acids for reducing disease risk have recently been called into question. Could this be due to variations in individual responses to ω3 intervention? We set out to determine whether comprehensive measurement of lipidomic profiles in response to 6 weeks supplementation with ω3 fatty acids (1.9 g/d eicosapentaenoic acid (EPA) and 1.5 g/d docosahexaenoic acid (DHA)) would reveal ω3 response phenotypes. Fatty acids, lipid classes, lipoprotein distribution, and oxylipins were examined. Multivariate analyses showed that lipidomic and oxylipin profiles changed significantly after supplementation across all subjects (p=0.00007 and p=0.00002 respectively). Oxylipin profiles were positively correlated with EPA and DHA in different lipid classes (r2=0.93). Individuals responded differently in both direction and magnitude across several key ω3 and ω6 fatty acid metabolites including prostaglandin E2 (PGE2) and thromboxane B2 (TXB2). Even among those metabolites that increased in response to supplementation in all subjects (e.g. EPA and DHA), there was a high degree of variability in magnitude of response. Lipoprotein particle distributions were driven mainly by gender. Individuals who were hyperresponders had distinct profiles from those who were hyporesponders. We used a lipidomic based phenotyping approach to determine whether differences in individual responsiveness to ω3 fatty acid supplementation could be used as a means to personalize ω3 interventions to modify disease risk.